Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

RENVELA ® TABLET 800MG [SIN13725P]

Active ingredients: ANHYDROUS SEVELAMER CARBONATE

View product's general information
Last updated on 9 October 2026

Product Info

RENVELA ® TABLET 800MG

[SIN13725P]

Product information

Active Ingredient and Strength

ANHYDROUS SEVELAMER CARBONATE - 800 MG

Dosage Form

TABLET, FILM COATED

Manufacturer and Country

SANOFI WINTHROP INDUSTRIE - FRANCE

Registration Number

SIN13725P

Licence Holder

SANOFI-AVENTIS SINGAPORE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

V03AE02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

1. INDICATIONS AND USAGE

Renvela is indicated for the control of hyperphosphataemia in adult patients receiving hemodialysis or peritoneal dialysis.

Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.

Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.

Dosing

2. DOSAGE AND ADMINISTRATION

Because of the rapid disintegration of the carbonate salt tablet and its rapid reaction with the hydrochloric acid in the stomach, the dosing of Renvela is anticipated to be similar to that of the hydrochloride salt.

Renvela should be given three times a day with meals.
Patients Not Taking a Phosphate Binder. The recommended starting dose of Renvela is 800 to 1600 mg, which can be administered as one or two Renvela 800 mg Tablets, with meals based on serum phosphorus level. Table 1 provides recommended starting doses of Renvela for patients not taking a phosphate binder.

Renvela Dosage Table 1



Patients Switching from Sevelamer Hydrochloride. For patients switching from sevelamer hydrochloride, sevelamer carbonate should be prescribed on a gram per gram basis. Further titration to the desired phosphate levels may be necessary. The highest daily dose of sevelamer carbonate studied was 14 grams in CKD patients on dialysis.

Patients Switching from Calcium Acetate. In a study in 84 CKD patients on hemodialysis, a similar reduction in serum phosphorus was seen with equivalent doses (approximately mg for mg) of sevelamer hydrochloride and calcium acetate. Table 2 gives recommended starting doses of Renvela based on a patient’s current calcium acetate dose.

Renvela Dosage Table 2



Dose Titration for All Patients Taking Renvela. The dose should be increased or decreased by one tablet per meal at two week intervals, as necessary, with the goal of controlling serum phosphorus within the target range of 3.5 mg/dL to 5.5 mg/dL.

Contraindications

4. CONTRAINDICATIONS

Renvela is contraindicated in patients with hypophosphatemia or bowel obstruction.
Renvela is contraindicated in patients with hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or to any of the excipients.